900 Walnut Street
Suite 200
Philadelphia, PA 19107
(215) 955-6871
(215) 503-2990 fax
Suite 200
Philadelphia, PA 19107
(215) 955-6871
(215) 503-2990 fax
Most Recent Peer-reviewed Publications
- Minimizing distortion through 'One piece flow - Heat treatment'
- Cladribine: Mode of action and implications for treatment of multiple sclerosis
- Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics
- Human optic nerve DTI with EPI geometric distortion correction
- Thickness of retinal nerve fiber layer correlates with disease duration in parallel with corticospinal tract dysfunction in untreated multiple sclerosis
- Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction
- Phase Labeling Using Sensitivity encoding (PLUS): Data acquisition and image reconstruction for geometric distortion correction in EPI
- When metals compete: A case of copper-deficiency myeloneuropathy and anemia
- Geometric distortion correction in EPI by phase labeling using sensitivity encoding (PLUS)
- Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up
- A phase I trial of interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis (Current Medical Research and Opinion (2006) 22, 9, (1671-1678) DOI: 10.1185/030079906X120931)
- The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation
- Commentary I: Pathophysiologic construct for neuronal degeneration/ regeneration in multiple sclerosis
- Commentary II: Clinical aspects of assessing neuronal health in multiple sclerosis
- MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis
- A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis
- Progressive necrotizing myelopathy: Part of the spectrum of neuromyelitis optica?
- Clinical-magnetic resonance imaging correlations in multiple sclerosis
- A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis
- Iriterferon-β1a therapy in human T-lymphotropic virus type I-associated neurologic disease
